Research and consultancy, Tabbush Report

Daniel Tabbush

Research and consultancy

Tabbush Report

We provide research and consultancy on Asian banks. Our focus is on what we call “Asian bank research, without the noise.” We are interested in the most critical swing-factors for banks, the NPL and credit cycle, and where we believe there is a gap between perception and reality. We often focus on the less studied components of bank financial statements.  Our research is highly thematic, sometimes examining unlisted banks and companies as a window on mainstream banks. 

Being independent allows us to look at smaller banks, often overlooked by others. Analysis of BIS bank guidelines in the context of Asia, is also a focal point, while we also analyze global banks operating in the region. We use what we believe is the most comprehensive, reliable financials database, SNL Financial. S&P Capital IQ augments our database, with corporate data and CEIC, with economics. 

Asian bank research, without the noise.

Equity Bottom-Up

<ul>
<li>Granular data from DBS shows worsening credit metrics in Greater China and in Hong Kong. </li>
<li>We use DBS and other banks, as a window on credit metrics for China banks and HK local banks.</li>
<li>The NPL ratio for its HK business moved from 1.1% to 1.7% YoY, while Pillar 3 data shows sharp rise in New NPLs in 2H24</li>
</ul>


Granular data from DBS shows worsening credit metrics in Greater China and in Hong Kong. 
We use DBS and other banks, as a window on credit metrics for China banks and HK local banks.
The NPL ratio for its HK business moved from 1.1% to 1.7% YoY, while Pillar 3 data shows sharp rise in New NPLs in 2H24


DBS - Granular Disclosure Shows Aggressive Deterioration in HK and China. Look at Pillar 3 Also.

Singapore Market Roundup, Singapore Market Roundup

Singapore Market Roundup

Thematic (Sector/Industry)

<ul><li>Singtel's FY2025 ebit growth guidance may rise to mid-to-high teens from successful cost cuts, according to CGSI.</li><li>IG predicts OCBC will reach $19 and UOB will hit $39.90 in share price.</li><li>SGX reports record revenue and profit in first half, with 1HFY2025 adjusted net profit up 27.3% and increased revenue across all segments. CEO Loh addresses succession concerns.</li></ul>

Singtel's FY2025 ebit growth guidance may rise to mid-to-high teens from successful cost cuts, according to CGSI.IG predicts OCBC will reach $19 and UOB will hit $39.90 in share price.SGX reports record revenue and profit in first half, with 1HFY2025 adjusted net profit up 27.3% and increased revenue across all segments. CEO Loh addresses succession concerns.

Singapore Market Roundup (06-Feb-2025): Singtel poised for strong ebit growth in FY2025 - CGSI

<ul><li>Singtel is considering raising their FY2025 ebit growth guidance to mid-to-high teens, attributed to successful cost cutting efforts according to CGSI.</li><li>IG forecast predicts OCBC stock may reach $19 and UOB may rise to $39.90. RHB increases Centurion's target price and earnings due to higher rate assumptions.</li><li>CGSI maintains 'add' rating for Genting Singapore despite slow tourism recovery. However, DBS and RHB cut CDLHT's target price due to Singapore hotel oversupply.</li></ul>

Singtel is considering raising their FY2025 ebit growth guidance to mid-to-high teens, attributed to successful cost cutting efforts according to CGSI.IG forecast predicts OCBC stock may reach $19 and UOB may rise to $39.90. RHB increases Centurion's target price and earnings due to higher rate assumptions.CGSI maintains 'add' rating for Genting Singapore despite slow tourism recovery. However, DBS and RHB cut CDLHT's target price due to Singapore hotel oversupply.

Singapore Market Roundup (05-Feb-2025): Singtel may raise FY2025 ebit growth guidance.

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, we had a look at the valuations for <a href="https://www.smartkarma.com/entities/dr-agarwal-s-eye-hospital" target="_blank" data-smartkarma-citation="entities:23713:1" rel="noopener">Dr. Agarwal’s Eye Hospital</a> and <a href="https://www.smartkarma.com/entities/seoul-guarantee-insurance-co" target="_blank" data-smartkarma-citation="entities:40123:1" rel="noopener">Seoul Guarantee Insurance (031210 KS)</a>. </li>
<li>On the placements front, given the holiday shortened week, there were no placements this week.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, we had a look at the valuations for Dr. Agarwal’s Eye Hospital and Seoul Guarantee Insurance (031210 KS). 
On the placements front, given the holiday shortened week, there were no placements this week.


ECM Weekly (3rd Feb 2025) - Seoul Guarantee, Dr Agarwal's, Ather Energy, Hexaware, Visen Pharma

<ul><li>Suntec REIT's future outlook uncertain, with analysts predicting lower estimates for FY2025-FY2026.</li><li>OUE REIT's performance post FY2024 results continues to divide opinions amongst analysts.</li><li>DBS maintains 'buy' rating and $3 target price for Seatrium, while reporting weak overseas assets for MPACT in 3QFY2025.</li></ul>

Suntec REIT's future outlook uncertain, with analysts predicting lower estimates for FY2025-FY2026.OUE REIT's performance post FY2024 results continues to divide opinions amongst analysts.DBS maintains 'buy' rating and $3 target price for Seatrium, while reporting weak overseas assets for MPACT in 3QFY2025.

Singapore Market Roundup (28-Jan-2025): Suntec REIT's FY2024 uncertain, lower estimates for FY2025-FY2026.

Singapore

Oversea-Chinese Banking Corporation Limited offers a comprehensive range of financial services.  The Company's services include deposit-taking, corporate, enterprise and personal lending, international trade financing, investment banking, private banking, treasury, stockbroking, insurance, credit cards, cash management, asset management and other financial and related services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

OCBC (OCBC SP)

DBS - Granular Disclosure Shows Aggressive Deterioration in HK and China. Look at Pillar 3 Also.

Granular disclosure in newly released data from DBS shows major deterioration in credit metrics in Hong Kong and in China. Its Pillar 3 release...

Daniel Tabbush

Singapore Market Roundup (06-Feb-2025): Singtel poised for strong ebit growth in FY2025 - CGSI

Singtel may raise FY2025 ebit growth guidance, OCBC and UOB shares expected to rise, SGX reports record revenue and profit in first half of year.

Singapore Market Roundup

Singapore Market Roundup (05-Feb-2025): Singtel may raise FY2025 ebit growth guidance.

Singtel may raise FY2025 ebit growth guidance, OCBC and UOB stocks may rise, Centurion's target price increased, Genting Singapore 'add' rating...

Singapore Market Roundup

ECM Weekly (3rd Feb 2025) - Seoul Guarantee, Dr Agarwal's, Ather Energy, Hexaware, Visen Pharma

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Singapore Market Roundup (28-Jan-2025): Suntec REIT's FY2024 uncertain, lower estimates for FY2025-FY2026.

Analysts divided on Suntec REIT's FY2024 but lower estimates for FY2025-FY2026 with predictions for DBS at $49, UOB at $42, OCBC at $19, OUE REIT...

Singapore Market Roundup

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)